Navipharm is rushing on patent challenges while Handok Teva had its debut

Competition to acquire the Priority Sale Item Approval Rights has been activated among generic pharmaceutical companies. The IP R&D company, Navipharm, has made sudden movements, facing the ‘Patent Linkage System’.

Moreover, Handok Teva, co-invested by the global generic company, Teva, and Handok, will have its debut. The industry is paying attention on movements of the company to participate ...